myelofibrosis
News/ News/ News/ Oncology/ R&D
GSK bolsters cancer pipeline with $1.9bn Sierra Oncology buy
Phil Taylor
GlaxoSmithKline, M&A, momelotinib, myelofibrosis, Oncology, Sierra Oncology
0 Comment
NICE changes tack on NHS use of BMS’ myelofibrosis drug Inrebic
Phil Taylor
Bristol-Myers Squib, Cancer Drugs Fund, Inrebic, JAK inhibitor, myelofibrosis, NHS, NICE
0 Comment
MorphoSys offers $1.7bn for Constellation, but investors see stars
Phil Taylor
Constellation Pharmaceuticals, Haematology, M&A, MorphoSys, myelofibrosis, Oncology, solid tumours
0 Comment
CTI wins over FDA to claim early review of myelofibrosis drug
Phil Taylor
CTI BioPharma, fda, Haematology, myelofibrosis, Oncology, pacritinib, thrombocytopenia
0 Comment
Celgene scores regulatory win ahead of BMS merger
Richard Staines
Bristol-Myers Squibb, Celgene, myelofibrosis
0 Comment